Alzamend Neuro Inc
ALZNHealthcare|Biotechnology|US
$1.41
-0.14 (-9.03%)
Tangible Book / Share
$1.30
Cash / Share
$1.70
Financials
Financial Snapshot
Market Cap
$6.8M
Enterprise Value
-$787.2K
Revenue (TTM)
$0.00
Net Income (TTM)
-$9.1M
Cash & Investments
$7.6M
Net Cash
$7.6M
Free Cash Flow (TTM)
-$6.8M
Operating CF (TTM)
-$6.8M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$7.6M
Quarterly Burn
$1.7M
Monthly Burn
$570.3K
Est. Runway
~4.4 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $5.0K | $545.0K | $42.6K | $90.3K | $1.9M | $14.1M | $5.1M | $376.0K | $3.9M | $710.7K | $7.6M | |
| Operating Cash Flow | -$1.4M | -$2.1M | -$1.0M | -$2.3M | -$2.7M | -$6.6M | -$8.9M | -$8.3M | -$6.6M | -$8.1M | -$6.8M | |
| Free Cash Flow | -$1.4M | -$2.1M | -$1.0M | -$2.3M | -$2.7M | -$6.7M | -$8.9M | -$8.4M | -$6.9M | -$8.1M | -$6.8M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$106.5K | $0.00 | -$147.2K | -$300.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $1.4M | $3.0M | $308.7K | $2.3M | $4.5M | $18.9M | $200.00 | $3.7M | $10.4M | $4.8M | $8.8M |
R&D Spending
R&D (TTM)
$3.0M
R&D Intensity
—
R&D Growth vs Prior
-18.0%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $275.0K | $323.4K | $3.7M | $1.1M | $1.3M | $5.2M | $7.4M | $6.5M | $1.4M | $3.6M | $3.0M | |
| SG&A | $1.3M | $575.0K | $1.3M | $3.4M | $3.6M | $7.1M | $7.4M | $3.5M | $3.1M | $5.1M | $6.1M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $55.4K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$55.4K | |
| R&D | $275.0K | $323.4K | $3.7M | $1.1M | $1.3M | $5.2M | $7.4M | $6.5M | $1.4M | $3.6M | $3.0M | |
| SG&A | $1.3M | $575.0K | $1.3M | $3.4M | $3.6M | $7.1M | $7.4M | $3.5M | $3.1M | $5.1M | $6.1M | |
| Operating Income | -$1.5M | -$898.0K | -$5.0M | -$4.4M | -$5.0M | -$12.3M | -$14.9M | -$9.9M | -$4.5M | -$8.8M | -$9.1M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $158.8K | $46.5K | $7.7K | $10.1K | $18.0K | -$6.6K | -$11.1K | |
| Pretax Income | -$1.6M | -$932.0K | -$4.9M | -$4.4M | -$5.0M | -$12.4M | -$14.9M | -$9.9M | -$4.5M | -$8.8M | -$9.1M | |
| Net Income | -$1.6M | -$932.0K | -$4.9M | -$4.4M | -$5.0M | -$12.4M | -$14.9M | -$9.9M | -$4.5M | -$8.8M | -$9.1M | |
| EPS (Diluted) | -73.59 | -27.71 | -111.56 | -83.56 | -93.78 | -187.31 | -205.97 | -132.33 | -11.32 | -2.63 | -2.30 | |
| EBITDA | $397.00 | $7.4K | -$5.0M | -$4.4M | -$5.0M | -$12.3M | -$14.8M | -$9.9M | -$4.4M | -$8.7M | -$9.0M | |
| Shares Out. (M) | 0.02 | 0.03 | 0.04 | 0.05 | 0.05 | 0.07 | 0.07 | 0.08 | 0.45 | 3.34 | 4.48 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.0K | $545.0K | $42.6K | $90.3K | $1.9M | $14.1M | $5.1M | $376.0K | $3.9M | $710.7K | $7.6M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $57.3K | $2.4M | $1.5M | $1.8M | $2.9M | $14.4M | $5.8M | $455.2K | $4.2M | $1.8M | $8.3M | |
| Total Assets | $132.3K | $2.4M | $1.5M | $1.8M | $2.9M | $14.5M | $5.9M | $631.6K | $4.6M | $2.1M | $8.5M | |
| Total Current Liabilities | $717.2K | $96.7K | $1.2M | $992.3K | $899.6K | $1.2M | $2.9M | $3.2M | $634.8K | $1.3M | $2.7M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $717.2K | $96.7K | $1.2M | $992.3K | $899.6K | $1.2M | $2.9M | $3.2M | $634.8K | $1.3M | $2.7M | |
| Stockholders' Equity | -$584.9K | $2.3M | $316.9K | $821.7K | $2.0M | $13.4M | $3.0M | -$2.6M | $4.0M | $733.2K | $5.8M | |
| Retained Earnings | -$1.6M | -$2.5M | -$7.4M | -$11.8M | -$16.8M | -$29.2M | -$44.1M | -$54.0M | -$58.5M | -$67.3M | -$70.3M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.4M | -$2.1M | -$1.0M | -$2.3M | -$2.7M | -$6.6M | -$8.9M | -$8.3M | -$6.6M | -$8.1M | -$6.8M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$106.5K | $0.00 | -$147.2K | -$300.0K | $0.00 | $0.00 | |
| Free Cash Flow | -$1.4M | -$2.1M | -$1.0M | -$2.3M | -$2.7M | -$6.7M | -$8.9M | -$8.4M | -$6.9M | -$8.1M | -$6.8M | |
| Investing Cash Flow | $0.00 | -$400.0K | $234.1K | $105.0K | $100.9K | -$106.5K | $0.00 | -$147.2K | -$300.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $1.4M | $3.0M | $308.7K | $2.3M | $4.5M | $18.9M | $200.00 | $3.7M | $10.4M | $4.8M | $8.8M | |
| Issuance of Stock | $0.00 | $3.6M | $236.0K | $2.3M | $2.1M | $18.9M | $200.00 | $1.3M | $2.7M | $794.8K | $8.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | -$364.1K | $0.00 | $0.00 | $402.1K | $0.00 | $0.00 | $300.0K | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $114.4K | $218.4K | $396.2K | $1.8M | $2.0M | $4.4M | $3.6M | $955.6K | $325.1K | $707.5K | $118.0K | |
| Net Change in Cash | $3.8K | $540.0K | -$502.4K | $47.7K | $1.8M | $12.1M | -$8.9M | -$4.8M | $3.6M | -$3.2M | $2.0M |
Dilution Tracker
Shares outstanding grew 6101.1% over 5 years — significant dilution
Shares Outstanding
5M
5-Year Share Growth
+6101.1%
Stock Issuance (TTM)
$8.8M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.02 | 0.03 | 0.04 | 0.05 | 0.05 | 0.07 | 0.07 | 0.08 | 0.45 | 3.34 | 4.48 | |
| Change vs Prior % | — | 57.6% | 29.6% | 21.1% | 2.0% | 22.6% | 9.5% | 4.1% | 499.7% | 640.3% | 34.2% | |
| Stock Issuance | $0.00 | $3.6M | $236.0K | $2.3M | $2.1M | $18.9M | $200.00 | $1.3M | $2.7M | $794.8K | $8.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $114.4K | $218.4K | $396.2K | $1.8M | $2.0M | $4.4M | $3.6M | $955.6K | $325.1K | $707.5K | $118.0K |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 268.4% | -40.2% | -1534.3% | -536.7% | -250.7% | -92.6% | -488.5% | 383.5% | -113.8% | -1196.4% | -277.9% | |
| ROA % | -1186.8% | -38.6% | -324.0% | -243.1% | -173.3% | -85.2% | -251.5% | -1575.0% | -98.1% | -421.9% | -106.5% | |
| ROIC % | -24462.7% | -38.7% | -1580.1% | -538.4% | -210.9% | -92.3% | -488.3% | 433.3% | -113.3% | -1195.7% | -156.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | -2128.7% | 42.0% | -457.8% | 11.7% | -11.9% | -148.8% | -20.7% | 33.2% | 54.7% | -95.0% | |
| Net Income | -2160.4% | 40.6% | -421.7% | 9.3% | -14.4% | -145.0% | -20.4% | 33.1% | 54.6% | -94.3% | |
| EPS (Diluted) | 0.0% | 62.3% | -302.6% | 25.1% | -12.2% | -99.7% | -10.0% | 35.8% | 91.4% | 76.8% | |
| Operating Cash Flow | -7561.1% | -44.8% | 49.1% | -124.4% | -15.6% | -143.9% | -34.9% | 7.3% | 20.6% | -22.8% | |
| Free Cash Flow | -7561.1% | -44.8% | 49.1% | -124.4% | -15.6% | -147.8% | -32.8% | 5.7% | 18.4% | -17.5% | |
| R&D Expense | 0.0% | 17.6% | 1044.1% | -71.1% | 22.6% | 296.8% | 43.2% | -13.3% | -78.1% | 156.5% | |
| SG&A Expense | 1732.8% | -54.8% | 127.6% | 156.3% | 8.5% | 95.5% | 4.3% | -53.1% | -11.5% | 66.7% | |
| Total Assets | 332.1% | 1726.3% | -37.9% | 20.9% | 60.6% | 398.4% | -59.2% | -89.3% | 628.8% | -54.8% | |
| Book Value / Share | 0.0% | 352.3% | -89.5% | 114.4% | 140.3% | 440.8% | -79.4% | -181.8% | 128.8% | -97.8% | |
| Debt | 18862.7% | -100.0% | 0.0% | -21.0% | 534955.1% | -100.0% | 0.0% | 0.0% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | 57.6% | 29.6% | 21.1% | 2.0% | 22.6% | 9.5% | 4.1% | 499.7% | 640.3% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.09
10Y Low / Med / High0.60 / 259.31 / 2472.82
EV/EBITDA0.09
10Y Low / Med / High0.36 / 80872.14 / 965519.60
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$1.30
Net Current Assets / Share
$1.14
Graham Net-Net
$1.08
Cash / Share
$1.70
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -247.66 | -657.70 | -163.37 | -218.11 | -194.34 | -7.35 | -3.48 | -0.48 | -0.52 | -0.43 | -0.61 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -654.31 | 259.31 | 2472.82 | 1153.33 | 479.86 | 6.70 | 16.96 | -1.85 | 0.60 | 5.19 | 1.09 | |
| EV/EBITDA | 965519.60 | 80872.14 | -156.45 | -214.87 | -194.81 | -6.13 | -3.13 | -0.48 | 0.36 | -0.36 | 0.09 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-12.77
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $31.6M | $132.7M | $32.2M |
| Net Income | -$3.5M | -$2.9M | -$2.9M |
| EPS | $-1.05 | $-0.87 | $-0.86 |
| # Analysts (EPS) | 1 | 1 | 1 |